Table 3.
Correlation of clinical, pathological and molecular features of metastatic tumors and length of patients’ survival.
| Clinical/molecular genetic feature | Total (%) | Short survival <1 year (%) | Long survival >1 year () | p-Value* |
|---|---|---|---|---|
| BAP1 LOH | 9/11 | 4/4 | 5/7 | 0.49 |
| Monosomy 3 | 4/11 | 4/4 | 0/7 | 0.003 |
| Partial chr 3/disomy 3 | 7/11 | 0/4 | 7/7 | 0.003 |
| 1p LOH | 5/10 | 3/4 | 2/6 | 0.52 |
| 8q LOH | 9/11 | 4/4 | 5/7 | 0.49 |
| 6p LOH | 6/10 | 3/4 | 3/6 | 0.57 |
| GNAQ or GNA11 mutation | 8/11 | 4/4 | 4/7 | 0.23 |
| Positive epitheliod cells | 6/11 | 4/4 | 2/7 | 0.06 |
| Strong tumor vasculature | 8/11 | 3/4 | 5/7 | 0.24 |
| Inflammatory infiltrate ≥5% | 7/10 | 0/3 | 7/7 | 0.008 |
| Lung/soft tissue | 2/11 | 0/4 | 2/7 | 0.49 |
| Liver metastasis | 9/11 | 4/4 | 5/7 | 0.49 |
| Female sex | 5/11 | 1/4 | 4/7 | 0.54 |
| Treatment with surgery/IHT | 5/11 | 0/4 | 5/7 | 0.06 |
| Age at metastasis <60 years | 7/11 | 1/4 | 6/7 | 0.088 |
| ≥48 months from initial diagnosis to metastasis | 7/11 | 1/4 | 6/7 | 0.088 |
| Metastasis in >1 organ | 8/11 | 3/4 | 5/7 | 1 |
| Prominent tumor necrosis | 4/11 | 1/4 | 3/7 | 1 |
| Ki-67 ≥ 10% | 8/11 | 4/4 | 4/7 | 0.24 |
| Prominent fibrosis | 4/11 | 1/4 | 3/7 | 1 |
*
Fisher’s exact test.